No­var­tis bol­sters Fab­hal­ta da­ta in com­pe­ti­tion with As­traZeneca

No­var­tis’ Fab­hal­ta im­proved he­mo­glo­bin lev­els in pa­tients with a rare blood dis­or­der who switched from an­ti-C5 ther­a­pies, bol­ster­ing the drug’s case against As­traZeneca’s com­pet­ing treat­ments …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER